Expanded Access for IMMU-132

N/AApproved For MarketingNCT04320693

Gilead Sciences

Overview

This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.

Study Type

EXPANDED_ACCESS

IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Exclusion Criteria: \-

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.